Improved Graft Function and Decreased Post-transplantation Urinary Tract Infection after Azithromycin Dosing to Donors: A Pilot Study
Urology Journal,
Vol. 22 No. 02 (2025),
2 March 2025
,
Page 89-94
https://doi.org/10.22037/uj.v22i.7988
Abstract
Purpose: The rising trend of End-stage Renal Disease (ESRD) patients requiring dialysis or transplantation needs a more therapeutic plan. As the best strategy for ESRD patients, kidney transplantation still needs outcome improvement. Macrolide drugs display antimicrobial and anti-inflammatory properties in chronic disease and intraoperatively and can concentrate in tissues for extended periods. Hence, theoretically, the drug prescription to the donor and accumulation in the kidney can cause graft immunomodulation and improve kidney transplantation outcomes.
Methods and Analysis: This double-blinded randomized clinical trial was conducted on 62 eligible kidney donors randomly allocated to the azithromycin or placebo group and treated with a single dose (one gram) one day before surgery. The primary outcome was kidney graft function, and secondary outcomes included rejection rate, urinary tract infections in graft recipients, pain and systemic inflammatory response syndrome in live donors, and complications in donors and recipients. Outcomes were measured at baseline and every day in the first week after transplantation in both live donors and recipients and 30 and 90 days after transplantation. The adverse events were recorded as well.
Result: The mean age was 39 (SD, 13) years; 40% were women, and 11.6% were diabetic. Mean creatinine was 6.11 mL/min/1.73m2. Most patients in both arms were male (61.3%) and in early middle age. Hypertension was the most common cause of ESRD. Azithromycin could reduce the rejection rate in the first few days after kidney transplantation. Inflammatory mediators were lower in the azithromycin group, and fewer cases of urinary tract infection were found in the azithromycin group (p < 0.05).
Conclusion: Azithromycin reduces adverse outcomes and enhances graft function. It would offer an intervention that is easy to use and economical, lowering post-transplant risks.
- Azithromycin; Kidney Transplantation; Immunomodulation; Graft Rejection; Transplant Recipients
How to Cite
References
Li Y, Ning Y, Shen B, Shi Y, Song N, Fang Y, et al. Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Clinical Kidney Journal. 2022;16:312-21.
Li PK, Chan GC, Chen J, Chen HC, Cheng YL, Fan SL, et al. Tackling Dialysis Burden around the World: A Global Challenge. Kidney Dis (Basel). 2021;7:167-75. Epub 2021/06/29.
Matas A, Smith J, Skeans M, Thompson B, Gustafson S, Schnitzler M, et al. OPTN/SRTR 2012 annual data report: kidney. American Journal of Transplantation. 2014;14:11-44.
Gill JS, Tonelli M, Johnson N, Pereira BJ. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation. 2004;78:873-9. Epub 2004/09/24.
Stellari FF, Sala A, Donofrio G, Ruscitti F, Caruso P, Topini TM, et al. Azithromycin inhibits nuclear factor-kappaB activation during lung inflammation: an in vivo imaging study. Pharmacology research & perspectives. 2014;2:e00058. Epub 2014/12/17.
Venditto VJ, Haydar D, Abdel-Latif A, Gensel JC, Anstead MI, Pitts MG, et al. Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Frontiers in immunology. 2021;12:574425. Epub 2021/03/02.
Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial agents and chemotherapy. 1989;33:277-82. Epub 1989/03/01.
Liu F, Dai S, Feng D, Qin Z, Peng X, Sakamuri S, et al. Distinct fate, dynamics and niches of renal macrophages of bone marrow or embryonic origins. Nature communications. 2020;11:2280. Epub 2020/05/10.
Mokhtari G, Teimoori M. Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial. Trials. 2018;19:345. Epub 2018/06/29.
United States Renal Data System.2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2017.
Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney international supplements. 2015;5:2-7. Epub 2015/06/23.
Jeong R, Quinn RR, Lentine KL, Lloyd A, Ravani P, Hemmelgarn B, et al. Outcomes Following Macrolide Use in Kidney Transplant Recipients. Canadian journal of kidney health and disease. 2019;6:2054358119830706. Epub 2019/03/01.
Tang YH, Yin CZ, Li K, Li WX, Fan CF. [Protective effects of azithromycin on adriamycin-induced nephropathy with albumin overload in mice]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology. 2019;35:548-50. Epub 2020/04/03.
Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. European Respiratory Journal. 2011;37:164-72.
Chow LW, Yuen KY, Woo PC, Wei WI. Clarithromycin attenuates mastectomy-induced acute inflammatory response. Clinical and diagnostic laboratory immunology. 2000;7:925-31. Epub 2000/11/04.
Eremenko AA, Chernova EV, Vinnitskii LI, Buniatian KA, Inviiaeva EV, Bogomolova NS, et al. [Effect of clarithromycin on the systemic inflammatory response syndrome severity in patients after myocardial revascularization surgery]. Anesteziologiia i reanimatologiia. 2012:67-71. Epub 2012/09/22.
Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respiratory research. 2010;11:90. Epub 2010/07/02.
Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57:212-6. Epub 2002/02/28.
Babalola OE NY, Ajayi AA, Ogedengbe JO, Thairu Y. 2021) A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID- 19 Patients in Nigeria. J Infect Dis Epidemiol 2021;7:233. .
Xu ZG, Gao Y, He JG, Xu WF, Jiang M, Jin HS. Effects of azithromycin on Pseudomonas aeruginosa isolates from catheter-associated urinary tract infection. Experimental and therapeutic medicine. 2015;9:569-72. Epub 2015/01/13.
Saini H, Chhibber S, Harjai K. Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections. International journal of antimicrobial agents. 2015;45:359-67. Epub 2015/01/22.
Amland PF, Andenaes K, Samdal F, Lingaas E, Sandsmark M, Abyholm F, et al. A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. Plastic and reconstructive surgery. 1995;96:1378-83. Epub 1995/11/01.
Romani L, Leon-Figueroa DA, Rafael-Navarro D, Barboza JJ, Rodriguez-Morales AJ. Association between the Use of Antibiotics and the Development of Acute Renal Injury in Patients Hospitalized for COVID-19 in a Hospital in the Peruvian Amazon. Journal of clinical medicine. 2022;11. Epub 2022/08/13.
- Abstract Viewed: 189 times
- 7988/pdf Downloaded: 116 times